Seer’s Proteomics Platform Named as Top 10 Innovation in 2022 by The Scientist
December 12 2022 - 10:00AM
Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a
disruptive new platform for proteomics, today announced that the
Proteograph Product Suite has been named one of The Scientist's
2022 Top 10 Innovations, an annual list that highlights the most
transformative and useful advances in life science technologies and
products poised to propel biomedical research forward.
Seer’s proprietary-engineered nanoparticle technology is
featured amongst pioneers in genomics and sequencing and is the
only proteomics technology honored on the list.
“Much like the genomics revolution twenty years ago, the field
of proteomics is on the cusp of achieving an explosive expansion in
the discovery of novel content, and this recognition shows that
Seer’s Proteograph Product Suite is at the forefront of this,” said
Serafim Batzoglou, Chief Data Officer at Seer. “The proteome is the
next frontier in human health, and Seer is committed to opening up
a new gateway to the proteome for researchers through our leading
technology.”
“Proteomics is more closely connected to phenotype than
genomics, and Seer’s technology makes it possible to uncover the
vast complexity of the proteome at scale and quantify protein
variants to study their role in health and disease,” said Mark
Flory, Ph.D., a research scientist at the Cancer Early Detection
Advanced Research Center of Oregon Health & Science
University’s Knight Cancer Institute. “By tracking changes in the
proteome, we can begin mapping disease trajectories and learn how
to intervene before illnesses become difficult to treat.”
To see the full list of The Scientist's 2022 Top 10 Innovations,
please visit their website.
About Seer
Seer is a life sciences company developing transformative
products that open a new gateway to the proteome. Seer’s
Proteograph™ Product Suite is an integrated solution that includes
proprietary engineered nanoparticles, consumables, automation
instrumentation and software to perform deep, unbiased proteomic
analysis at scale in a matter of hours. Seer designed the
Proteograph workflow to be efficient and easy to use, leveraging
widely adopted laboratory instrumentation to provide a
decentralized solution that can be incorporated by nearly any lab.
Seer’s Proteograph Product Suite is for research use only and is
not intended for diagnostic procedures. For more information,
please visit www.seer.bio.
Forward-Looking StatementsThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended. Such
forward-looking statements are based on Seer’s beliefs and
assumptions and on information currently available to it on the
date of this press release. Forward-looking statements may involve
known and unknown risks, uncertainties and other factors that may
cause Seer’s actual results, performance, or achievements to be
materially different from those expressed or implied by the
forward-looking statements. These statements include but are not
limited to statements regarding Seer’s Proteograph Product Suite,
its ability to uncover the vast complexity of the proteome at
scale, discover novel content, and ability to map disease. These
and other risks are described more fully in Seer’s filings with the
Securities and Exchange Commission (“SEC”) and other documents that
Seer subsequently files with the SEC from time to time. Except to
the extent required by law, Seer undertakes no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made.
Investor ContactCarrie Mendivilinvestor@seer.bio
Media ContactKaren Possematopr@seer.bio
Seer (NASDAQ:SEER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Seer (NASDAQ:SEER)
Historical Stock Chart
From Jul 2023 to Jul 2024